STOKE THERAPEUTICS INC (STOK) Stock News

USA - NASDAQ:STOK - US86150R1077 - Common Stock

26.51 USD

+0.44 (+1.69%)

Last: 11/14/2025, 8:00:00 PM

27 USD

+0.49 (+1.85%)

After Hours: 11/14/2025, 8:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

STOK Latest News, Press Relases and Analysis

All

Press Releases

10 days ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

10 days ago - By: Zacks Investment Research

All You Need to Know About Stoke Therapeutics (STOK) Rating Upgrade to Buy

10 days ago - By: Benzinga

6 Analysts Have This To Say About Stoke Therapeutics

10 days ago - By: Zacks Investment Research - Mentions: IOVA

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates

11 days ago - By: Benzinga - Mentions: ACET RIGL TEM AKTX ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

11 days ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

16 days ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates

26 days ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)

a month ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

a month ago - By: Stoke Therapeutics, Inc. - Mentions: BIIB

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

a month ago - By: Biogen Inc. - Mentions: BIIB

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

a month ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer

2 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

2 months ago - By: Stoke Therapeutics, Inc. - Mentions: BIIB

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

2 months ago - By: Biogen Inc. - Mentions: BIIB

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

3 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025

3 months ago - By: Stoke Therapeutics, Inc. - Mentions: BIIB

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

3 months ago - By: Biogen Inc. - Mentions: BIIB

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

3 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

3 months ago - By: Zacks Investment Research - Mentions: MRSN

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

3 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

3 months ago - By: Stoke Therapeutics, Inc. - Mentions: BIIB

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

3 months ago - By: Biogen Inc. - Mentions: BIIB

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

3 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates

3 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

3 months ago - By: Zacks Investment Research - Mentions: MRUS

Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates

4 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Stoke Therapeutics, Inc. - Mentions: BIIB

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

4 months ago - By: Biogen Inc. - Mentions: BIIB

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress